Peer-reviewedLicence not statedJournal Français d'Ophtalmologie
Fédération France Macula Practical Guidelines for the Use of Anti-VEGF Biosimilars
Related
- Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
- Long-Term Experience in the Molecular Genetic Diagnosis of Friedreich Ataxia in the Russian Federation
- The World Federation of ADHD International Consensus Statement: 2026 Update
- Contributions of World Federation of Neurology Specialty Groups to brain health, with a public health perspective
- Neurocognition of dance: Guidelines for using dance as model behavior and research subject in cognitive neuroscience
BibTeX
@article{ghazi2026fédération,
title = {{Fédération France Macula Practical Guidelines for the Use of Anti-VEGF Biosimilars}},
author = {D. El Ghazi and M. Srour and H. Oubraham and J.F. Korobelnik and L. Kodjikian and O. Semoun and S.Y. Cohen and S. Razavi and C. Danese and F. Amoroso and C.J. Mehanna and A. Miere and E. Souied},
journal = {Journal Français d'Ophtalmologie},
year = {2026},
month = oct,
doi = {10.1016/j.jfo.2026.104981},
url = {https://hal.science/hal-05795308v1},
}
RIS
TY - JOUR
TI - Fédération France Macula Practical Guidelines for the Use of Anti-VEGF Biosimilars
AU - D. El Ghazi
AU - M. Srour
AU - H. Oubraham
AU - J.F. Korobelnik
AU - L. Kodjikian
AU - O. Semoun
AU - S.Y. Cohen
AU - S. Razavi
AU - C. Danese
AU - F. Amoroso
AU - C.J. Mehanna
AU - A. Miere
AU - E. Souied
PY - 2026
DA - 2026/10/12
JO - Journal Français d'Ophtalmologie
DO - 10.1016/j.jfo.2026.104981
UR - https://hal.science/hal-05795308v1
SN - 0181-5512
SN - 1773-0597
ER -